Latest Conference Articles

CEE therapy alone in postmenopausal women after hysterectomy was linked to a substantial increase in ovarian cancer incidence and mortality.

Antoni Vilaseca Cabo, MD, discusses phase 1 data presented on TAR-210 for the treatment of patients with FGFR-altered high- and intermediate-risk non-muscle invasive bladder cancer.

The American Urological Association Annual Meeting took place May 3-6, 2024, in San Antonio, Texas, where data across the field of urologic oncology were presented.

Sima Porten, MD, MPH, discusses the rationale for the phase 3 SunRISe-5 study of TAR-200 in non-muscle invasive bladder cancer and unmet needs in this patient population.

Darolutamide has been adopted routinely in clinical practice as a component of both doublet and triplet regimens for the treatment of patients with metastatic hormone-sensitive prostate cancer.

Non-muscle invasive bladder cancer treatment with TAR-210 demonstrated safety and clinical activity in FGFR-altered high- and intermediate-risk patient groups.

In patients at 15 centers who had upper tract urothelial cancer, those with no evidence of disease after UGN-101 induction had a 68% rate of 3-year recurrence-free survival, and this outcome did not differ based on tumor status, method of instillation, or treatment intent.

Nadofaragene firadenovec maintained its durable clinical activity at 5 years in patients with high-risk, BCG-unresponsive non–muscle-invasive bladder cancer.

Maintenance UGN-101 therapy demonstrated good durability of response in initial responders with low-grade upper tract urothelial cancer, as evidenced by a low rate of disease progression in a multicenter, longitudinal follow-up study.

Combination therapy with nivolumab and gemcitabine-cisplatin showed promising results in treating metastatic urothelial carcinoma with significantly improved overall survival and progression-free survival rates.

Combination nivolumab and nab-paclitaxel may be a safe and effective treatment for patients with muscle-invasive bladder cancer.

Roger Li, MD, discusses what the future may hold for the use of TAR-210 for the treatment of patients with intermediate-risk non-muscle-invasive bladder cancer with susceptible FGFR alterations.

A study found that UGN-102, used alone or combined with TURBT, resulted in comparable duration of response and disease-free survival rates in both patients newly diagnosed with and those with recurrent low-grade/intermediate non-muscle invasive bladder cancer.

The addition of PSMA-PET imaging to multi-parametric MRI was associated with an improvement in the detection of clinically significant prostate cancer.

Treatment with enzalutamide alone and with leuprolide delivered higher rates of undetectable PSA levels compared with leuprolide alone in patients with castration-sensitive prostate cancer.

Improved outcomes with lutetium Lu 177 vipivotide tetraxetan vs ARPI change supported prior treatment with abiraterone vs enzalutamide in mCRPC.

Stephen Williams, MD, discusses the phase 3 SunRISe-2 study investigating TAR-200 plus cetrelimab in muscle-invasive bladder cancer being presented at the 2024 American Urological Association Annual Meeting.

EG-70, a novel, nonviral gene therapy, elicited a 73% complete response at any time for patients with non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ.

Treatment with TAR-200 displayed a high complete response rate in Bacillus Calmette-Guérin-unresponsive high-risk non-muscle-invasive bladder cancer.

Patients who underwent extended lymph node dissection during radical cystectomy compared with those who underwent standard lymph node dissection exhibited no benefit in disease-free survival or overall survival.

Data support using 18F-PSMA-1007 PET/CT in the preoperative workflow of intermediate- and high-risk prostate cancer.

Administering high-intensity focused ultrasound could be a noninferior treatment option for patients with localized prostate cancer, according to a prospective trial.

Apalutamide with androgen deprivation therapy following radical prostatectomy led to a biochemical recurrence-free survival rate of 100% after 2 years among patients with high-risk prostate cancer.

Mark D. Tyson, II, MD, MPH, discusses the safety and efficacy findings from the BOND-003 trial of cretostimogene grenadenorepvec in high-risk Bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer with carcinoma in situ.

In the phase 3 BOND-003 trial, cretostimogene grenadenorepvec led to durable complete responses over 12 months among patients with high-risk BCG-unresponsive non-muscle-invasive bladder cancer with carcinoma in situ.

Mark D. Tyson, II, MD, MPH, discusses the background of the phase 3 BOND-003 study evaluating cretostimogene grenadenorepvec in patients with high-risk Bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer with carcinoma in situ.

Mark D. Tyson, II, MD, MPH, concludes his conversation on the BOND-003 trial by discussing the next steps for research on cretostimogene grenadenorepvec.

Warren Fingrut, MD, discussed a study looking at HLA antibody burden among patients with blood cancers, particularly women who have carried multiple pregnancies.

Rahul Banerjee, MD, discusses new frontiers in the treatment of multiple myeloma with CAR T-cell therapy.

Alex Chehrazi-Raffle, MD, discusses findings from a real-world analysis of adjuvant treatment in bladder cancer presented at ASCO GU.